[1] |
PENG Zishan, KONG Hui, BAO Zhen, ZHAO Hongxing, LIU Xin, LU Shaohua.
Clinicopathological analysis of 83 cases of multifocal lung adenocarcinoma
[J]. China Oncology, 2021, 31(5): 408-418.
|
[2] |
ZHAO Yuanyuan , ZHOU Jianying , FAN Yun , WANG Jialei , HUANG Dingzhi , LI Junling , SHI Meiqi , LIU Jiwei , YAO Yu , WU Lin , YAO Wenxiu , ZHANG Li .
Advances in the treatment of BRAF V600-mutant non-small cell lung cancer
[J]. China Oncology, 2021, 31(12): 1145-1152.
|
[3] |
HE Xi, JIAO Xiaodong, ZANG Yuansheng.
Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer
[J]. China Oncology, 2021, 31(1): 69-75.
|
[4] |
CHEN Xinning , WANG Beili , GUO Wei .
Impact of clonal hematopoiesis on the detection of somatic mutation
[J]. China Oncology, 2020, 30(9): 707-711.
|
[5] |
ZHU Lihua , NI Tingting , FAN Xingwen , WU Kailiang .
Comparison of prognostic scoring systems in patients with EGFR-mutant lung cancer and brain metastases
[J]. China Oncology, 2020, 30(8): 605-610.
|
[6] |
REN Chunxia,XIA Xiaoai,YANG Shudong,LV Bei,TONG Guoqing .
Establishment and initial analysis of an immortalized human ovarian surface epithelial cell line carrying a BRCA1 mutation
[J]. China Oncology, 2019, 29(9): 693-699.
|
[7] |
ZHANG Ling, ZHOU Xiaoyan, CHEN Ying, ZHANG Hao, GAO Lili, WANG Yu, JI Qinghai, PING Bo, ZHU Xiaoli.
Clinical significance of BRAF V600E detection in fine-needle aspiration samples of thyroid nodule
[J]. China Oncology, 2019, 29(3): 178-182.
|
[8] |
ZHONG Jian , JIN Zhengxian , BIAN Weixing , QIU Jiaxing , HOU Jianquan .
Effects of FGFR3 and PIK3CA mutations on prognosis of bladder carcinoma
[J]. China Oncology, 2019, 29(11): 880-886.
|
[9] |
GAO Zhiqiang,WANG Weimin,CAI Yuqing,QIN Ruoyan,GU Aiqin,XIONG Liwen,HAN Baohui,JIANG Liyan,SHI Chunlei .
Clinical efficacy of osimertinib in the treatment of 62 patients with advanced lung adenocarcinoma
[J]. China Oncology, 2019, 29(10): 809-814.
|
[10] |
LIANG Xiaohua, HUANG Ruofan, ZHAN Qiong.
Shanghai expert consensus on the management of brain metastasis of non-small cell lung cancer with driver gene mutations
[J]. China Oncology, 2019, 29(1): 71-80.
|
[11] |
YU Baohua, XUE Tian, ZHANG Yan, et al.
MYD88 gene mutation in diffuse large B-cell lymphoma and its clinicopathological relevance
[J]. China Oncology, 2018, 28(9): 679-685.
|
[12] |
WU Junlong, GU Weijie, QIN Xiaojian, et al.
Study on BRCA1/2 and ATM germline mutations in the Chinese prostate cancer patients
[J]. China Oncology, 2018, 28(8): 584-589.
|
[13] |
SHENG Dong, WANG Weige, JIANG Xiangnan, et al.
Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a clinicopathological study of 10 cases with detection of MYD88 L265P mutation
[J]. China Oncology, 2018, 28(12): 900-905.
|
[14] |
ZHAO Haiyun, JI Peng, LI Xiaoguang, et al.
Research progress of biomarkers associated with efficacy of immune checkpoint blockade
[J]. China Oncology, 2018, 28(11): 852-857.
|
[15] |
CHEN Jie, WANG Chunmeng, LUO Peng, et al.
Gene expression profiling of c-kit wild type and mutant tumors in gastrointestinal stromal tumor
[J]. China Oncology, 2018, 28(1): 50-54.
|